Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug
You may also be interested in...
Rolofylline fails to meet primary and secondary endpoints in a Phase III trial.
Trevena has carved out a niche in seeking so-called 'biased ligands'--GPCR-binding compounds that selectively activate just one (or a few) of the many biological pathways mediated via a particular GPCR complex. By identifying a ligand that hits the pathways responsible for a medicine's benefits, and avoiding those behind the ill effects, the company hopes to develop safer and more effective therapies, initially in CNS and cardiovascular disease.
Despite several setbacks this year, and a major competitor's withdrawal from further R&D in the field, Merck reiterated its commitment to cardiovascular R&D at its annual business review Dec. 9 and outlined an aggressive cardiovascular development program